You are here: Home » News-IANS » Health-Medicine
Business Standard

Coming: A pill to boost your compassion

IANS  |  New York 

In a big step towards developing a pill that could make you more egalitarian, researchers have found that a drug that prolongs the effects of the brain chemical dopamine boosts compassion.

Dopamine is a brain chemical associated with reward and motivation in the prefrontal cortex of the brain.

In the study, published online in the journal Current Biology, the researchers used the drug tolcapone, which is already approved by the US Food and Drug Administration (FDA) for use in treatment of people with Parkinson's disease.

"We typically think of fair-mindedness as a stable characteristic, part of one's personality," said co-principal investigator Ming Hsu, assistant professor at the University of California - Berkeley.

"Our study does not reject this notion, but it does show how that trait can be systematically affected by targeting specific neurochemical pathways in the human brain," Hsu noted.

The study involved 35 participants, including 18 women. On two separate visits, the study participants received a pill containing either a placebo or tolcapone that prolongs the effects of dopamine.

Participants then played a simple economic game in which they divided money between themselves and an anonymous recipient.

After receiving tolcapone, participants divided the money with the strangers in a fairer, more egalitarian way than after receiving the placebo.

Previous studies had shown that economic inequity is evaluated in the prefrontal cortex, a core area of the brain that dopamine affects,

"We have taken an important step toward learning how our aversion to inequity is influenced by our brain chemistry," first author of the current study Ignacio Saez from the UC Berkeley pointed out.

"Studies in the past decade have shed light on the neural circuits that govern how we behave in social situations. What we show here is one brain 'switch' we can affect," Saez noted.

Dear Reader,


Business Standard has always strived hard to provide up-to-date information and commentary on developments that are of interest to you and have wider political and economic implications for the country and the world. Your encouragement and constant feedback on how to improve our offering have only made our resolve and commitment to these ideals stronger. Even during these difficult times arising out of Covid-19, we continue to remain committed to keeping you informed and updated with credible news, authoritative views and incisive commentary on topical issues of relevance.
We, however, have a request.

As we battle the economic impact of the pandemic, we need your support even more, so that we can continue to offer you more quality content. Our subscription model has seen an encouraging response from many of you, who have subscribed to our online content. More subscription to our online content can only help us achieve the goals of offering you even better and more relevant content. We believe in free, fair and credible journalism. Your support through more subscriptions can help us practise the journalism to which we are committed.

Support quality journalism and subscribe to Business Standard.

Digital Editor

First Published: Fri, March 20 2015. 12:38 IST
RECOMMENDED FOR YOU
RECOMMENDED FOR YOU